MR 409
Modify Date: 2024-01-03 14:34:21
MR 409 structure
|
Common Name | MR 409 | ||
|---|---|---|---|---|
| CAS Number | 1445155-39-4 | Molecular Weight | 3395.91 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C153H252N44O43 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of MR 409MR 409 is a selected growth hormone-releasing hormone (GHRH) agonist. MR 409 has remarkable neuroprotective effects through enhancing endogenous neurogenesis in cerebral ischemic mice. MR 409 also inhibits the in vivo growth of lung cancer[1][2][3][4]. |
| Name | MR 409 |
|---|
| Description | MR 409 is a selected growth hormone-releasing hormone (GHRH) agonist. MR 409 has remarkable neuroprotective effects through enhancing endogenous neurogenesis in cerebral ischemic mice. MR 409 also inhibits the in vivo growth of lung cancer[1][2][3][4]. |
|---|---|
| Related Catalog | |
| In Vitro | One week post-myocardial infarction (MI), MR 409 (MR-409) significantly reduces plasma levels of IL-2, IL-6, IL-10 and TNF-α compared to placebo[1]. MR 409 (MR-409; 1 μM) suppresses p53 expression in bovine pulmonary arterial endothelial cells (BPAECs)[2]. MR 409 (1 μM) induces the activation of JAK2, STAT3 and ERK1/2[2]. MR 409 (MR-409; 1 and 5 μM) decreases LPS-induced PGE2 and 8-iso-PGF2α levels, in a dose-dependent manner[3]. MR 409 (1 and 5μM) decreases LPS-induced lactate dehydrogenase (LDH) activity and nitrite production, without showing a dose-dependent effect[3]. MR 409 (1 and 5 μM) decreases LPS-induced gene expression of COX-2, NF-κB and iNOS in colon specimens, without a dose-dependent effect[3]. MR 409 (MR-409) can stimulate endogenous neurogenesis and improve the tMCAO-induced loss of neuroplasticity. MR 409 also enhances the proliferation and inhibits apoptosis of neural stem cells treated with oxygen and glucose deprivation-reperfusion[4]. Western Blot Analysis[2] Cell Line: BPAEC Concentration: 1 μM Incubation Time: 24, 48 and 72 hours Result: Significantly suppressed p53 expression levels after 48 and 72 hours of treatment. |
| In Vivo | MR 409 (MR-409) inhibits the in vivo growth of lung cancer xenografted into nude mice[3]. MR 409 (5 μg; s.c. treated daily for 4 weeks) reduces nociceptive response in mice[3]. Animal Model: Adult C57/BL6 male mice (5 weeks old, weight 20-22 g)[3] Dosage: 5 µg Administration: Treated daily by subcutaneous (s.c.) administration of 0.1 mL solution Result: Showed maximal antinociceptive effects at 2 weeks. Sustained a moderate analgesic effect at 4 weeks. |
| References |
| Molecular Formula | C153H252N44O43 |
|---|---|
| Molecular Weight | 3395.91 |